Although CD137 agonists have not yet been tested clinically in sepsis, the emergence of more well tolerated bispecific antibodies targeting CD137 in oncology offers new hope for translating this approach to the treatment of patients with septic shock (72, 73). Here, TNFRSF9 is linked to Sepsis.